HOPKINTON, MASSACHUSETTS — September 17, 2025 — Leads & Copy — Keensight Capital has acquired a majority stake in Isto Biologics from Thompson Street Capital Partners (TSCP). TSCP will retain a minority stake, alongside Isto Biologics’ management team.
Founded in 2016, Isto Biologics develops and manufactures orthobiologic products to help patients heal faster. Isto’s product offering covers six functional areas of bone graft solutions and includes a range of allografts, used for bone repair in the spine. Isto sells its products to more than 400 hospitals and clinics, used in 15,000 surgical procedures per month, primarily in the United States.
Keensight will leverage its experience to further grow Isto into a global leader in biomaterials for tissue regeneration. Keensight will contribute to accelerating Isto’s growth strategy, both organically and through acquisitions.
Isto Biologics CEO, Don Brown, said they are looking forward to working with Keensight as they enter the next phase of their growth. Amit Karna and David Piccoli, Partners at Keensight Capital, added that they have been tracking Isto specifically for more than 5 years. Jesse Klein, Managing Director at Thompson Street Capital Partners, concluded that their partnership with Isto has been extremely successful.
Jessica Kemp, Marketing Director – jkemp@istobiologics.com +1 (774) 230-7125
Source: Isto Biologics
